The FDA is proposing to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list, determining there is no clinical need for outsourcing facilities to compound these drugs. The action affects the ability of compounding pharmacies to prepare these GLP-1 medications from bulk substances.